PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Video: Paradigm Biopharmaceuticals (ASX:PAR) conducting Phase 3 osteoarthritis trial, page-15

  1. 9,808 Posts.
    lightbulb Created with Sketch. 1243

    From what I understand (second hand) SW has already started and will continue to challenge PAR's strategy. He now has a seat at the table to ensure they're completely focused on what matters and push back on what doesn't.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.